Our plucked hair biomarker platform has been extensively mined to identify pathways that can be modulated by therapeutics in ex vivo hair cultures. We have developed qPCR and NGS panels using these targets for endpoint analysis of target engagement for a variety of drug targets such as PI3-Kinase inhibitors.
Derived from laser capture microdissected clinical samples from lung, liver and kidney fibrosis patients we offer qPCR and NGS panels for identification of fibrotic markers and their modulation by therapeutic agents.
Pre-designed or custom designed panels are available upon request. Both our NextSeq 550 and Fluidigm systems provide excellent platforms for targeted resequencing and target validation for cost-effective confirmation of potential biomarkers.